Leerink Partners Rates Rapport Therapeutics (RAPP) buy

Leerink Partners maintains its buy rating on RAPP, setting a target price of $52, a 30% upside from the current price.

By EarningsIQ Research Desk · Published Jun 24, 2026, 3:01 PM EDT · Updated Jun 26, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Leerink Partners rated Rapport Therapeutics, Inc. ($RAPP) "buy" with a $52 price target on June 24, 2026.

Since the rating, $RAPP is down 1.5% after 1 week, up 1.7% after 1 month and down 31.1% to date (from the $40 close on Jun 24, 2026).

RAPP Rapport Therapeutics, Inc.

$27.57 -1.92% year to date

Daily close · Oct 16, 2026

Key Points

Leerink Partners reiterated its buy rating on RAPP on June 24, 2026, with a price target of $52.
Leerink Partners's $52 price target implies 30% upside from Rapport Therapeutics, Inc.'s ($RAPP) current $40 share price.
RAPP shares traded near $38.88 on Wednesday, with recent insider buying activity noted.
Peers like FMR LLC and TRV GP V, LLC hold significant shares in RAPP, with varied recent activity.

Get $RAPP trade alerts by text

We text you when insiders, Congress or big funds trade $RAPP. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Rapport Therapeutics, Inc. alert may contain errors. Disclosures

On June 24, 2026, Leerink Partners reaffirmed its buy rating on RAPP, setting a price target of $52. Analyst Marc Goodman led the review, indicating confidence in the stock's potential. RAPP shares were trading close to $38.88 on Wednesday.

Analyst rating track record

Leerink Partners vs. the S&P 500

YTD return +40.05% hypothetical

All-time return +40.05% S&P 500 +5.91%

vs. S&P 500 +34.14% ahead of the index

Hypothetical returns from Leerink Partners's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in RAPP

FMR LLC increased its holdings in RAPP by 57,074 shares, bringing its total to about 7.17 million shares valued at approximately $224.3 million. TRV GP V, LLC maintained its position with around 7.14 million shares worth $223.3 million. ARCH VENTURE MANAGEMENT, LLC also held steady with about 3.73 million shares valued at $116.7 million. Meanwhile, CAPITAL INTERNATIONAL INVESTORS reduced its stake by 304,556 shares, now holding about 3.10 million shares valued at $96.9 million. CORMORANT ASSET MANAGEMENT, LP cut its holdings by 70,000 shares, ending with approximately 2.96 million shares worth $92.5 million.

Insider Buying and Selling at Rapport Therapeutics, Inc.

On June 10, 2026, several insiders, including John Maraganore, Paul Silva, Wendy Young, Ramiro Sanchez, James Healy, and Reid Huber, each bought 15,200 shares of RAPP. These transactions were not part of any pre-arranged trading plan.

Analysts Set New Price Targets

On June 24, 2026, Leerink Partners reiterated its buy rating for RAPP with a $52 price target. Previously, on May 21, 2026, BTIG maintained a buy rating with a $65 target, and on May 19, 2026, Truist Securities assumed a buy rating with a $56 target. The consensus rating for RAPP remains a buy, with an average target price reflecting optimism among analysts.

Bottom Line

Leerink Partners' reiteration of a buy rating for RAPP suggests continued confidence in the company's prospects. The stock, trading near $38.88, is supported by insider buying and significant institutional holdings. While analyst targets vary, the overall sentiment remains positive, reflecting expectations of growth.

12-month forecast